Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024
Nasolacrimal Duct Obstruction Following Radioactive Iodine: An Update on Counseling Recommendations for Thyroid Cancer Survivors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Homer Natalie A, Desai Kaniksha
Аннотация
OBJECTIVE: Radioactive iodine (RAI) treatment for thyroid carcinoma may induce nasolacrimal duct obstruction. Evidence-based recommendations regarding nasolacrimal screening and prophylactic management in thyroid cancer survivors are lacking.
METHODS: A case control study of patients treated with radioactive iodine for thyroid carcinoma was performed, comparing those who developed symptomatic nasolacrimal duct obstruction (group 1) to age- and gender-matched controls who did not develop nasolacrimal duct obstruction (group 2), to identify risk factors.
RESULTS: Fifty patients with history of RAI treatment for thyroid carcinoma were reviewed, including 25 patients who subsequently developed epiphora and were diagnosed with nasolacrimal duct obstruction, and 25 age- and gender-matched RAI-treated patients who did not develop nasolacrimal duct obstruction. The mean cumulative RAI dose was 223.4 mCi (8.27 Gbq) for group 1 and 121.4 mCi (4.49 Gbq) for group 2 (P = .0092). The mean initial treatment dose was 128.9 mCi (4.77 Gbq) and 100.0 mCi (3.70 Gbq) for the 2 groups, respectively (P = .0317). The mean number of RAI treatment sessions in patients who developed nasolacrimal duct obstruction was 1.48 (range 1-3), compared to 1.16 (range 1-2) in the group that did not (P = .0387).
CONCLUSIONS: Higher initial and cumulative treatment dose of RAI, and multiple treatment sessions, increased likelihood of subsequent development of nasolacrimal duct obstruction. We recommend increased counseling and screening of thyroid cancer survivors undergoing RAI for thyroid carcinoma at lower doses than previously indicated, particularly in those who undergo multiple treatment sessions.
METHODS: A case control study of patients treated with radioactive iodine for thyroid carcinoma was performed, comparing those who developed symptomatic nasolacrimal duct obstruction (group 1) to age- and gender-matched controls who did not develop nasolacrimal duct obstruction (group 2), to identify risk factors.
RESULTS: Fifty patients with history of RAI treatment for thyroid carcinoma were reviewed, including 25 patients who subsequently developed epiphora and were diagnosed with nasolacrimal duct obstruction, and 25 age- and gender-matched RAI-treated patients who did not develop nasolacrimal duct obstruction. The mean cumulative RAI dose was 223.4 mCi (8.27 Gbq) for group 1 and 121.4 mCi (4.49 Gbq) for group 2 (P = .0092). The mean initial treatment dose was 128.9 mCi (4.77 Gbq) and 100.0 mCi (3.70 Gbq) for the 2 groups, respectively (P = .0317). The mean number of RAI treatment sessions in patients who developed nasolacrimal duct obstruction was 1.48 (range 1-3), compared to 1.16 (range 1-2) in the group that did not (P = .0387).
CONCLUSIONS: Higher initial and cumulative treatment dose of RAI, and multiple treatment sessions, increased likelihood of subsequent development of nasolacrimal duct obstruction. We recommend increased counseling and screening of thyroid cancer survivors undergoing RAI for thyroid carcinoma at lower doses than previously indicated, particularly in those who undergo multiple treatment sessions.